Abstract Olfactory receptors (ORs) belong to the superfamily of G protein-coupled receptors (GPCRs), the second largest class of genes after those related to immunity, and account for about 3 % of mammalian genomes. ORs are present in all multicellular organisms and represent more than half the GPCRs in mammalian species (e.g., the mouse OR repertoire contains >1,000 functional genes). ORs are mainly expressed in the olfactory epithelium where they detect odorant molecules, but they are also expressed in a number of other cells, such as sperm cells, although their functions in these cells remain mostly unknown. It has recently been reported that ORs are present in tumoral tissues where they are expressed at different levels than in healthy tissues. A specific OR is overexpressed in prostate cancer cells, and activation of this OR has been shown to inhibit the proliferation of these cells. Odorant stimulation of some of these receptors results in inhibition of cell proliferation. Even though their biological role has not yet been elucidated, these receptors might constitute new targets for diagnosis and therapeutics. It is important to understand the activation mechanism of these receptors at the molecular level, in particular to be able to predict which ligands are likely to activate a particular receptor ('deorphanization') or to design antagonists for a given receptor. In this review, we describe the in silico methodologies used to model the three-dimensional (3D) structure of ORs (in the more general framework of GPCR modeling) and to dock ligands into these 3D structures.
Introduction
G protein-coupled receptors (GPCRs) are a highly versatile family of membrane proteins that allow the cell to detect extracellular signals and trigger specific cellular responses to these signals via downstream activators such as G proteins or β-arrestins (Luttrell et al. 1999) . In turn, these activators elicit a cascade of cellular events through the activation of effectors, including calcium channels, adenylate cyclase, phospholipase C, among others (Hamm 1998; Ronnett and Moon 2002) . GPCRs respond to a wide set of external and endogenous stimuli, such as light (photons), odors, pheromones, hormones, and neurotransmitters and are associated with a large array of biological functions, including vision, olfaction, taste, pain, etc. Consequently, GPCRs are involved in a variety of pathologies and are the therapeutic target of a large number of prescription drugs, as evidenced by the introduction of 63 GPCR drugs on the market in the past decade, corresponding to 24 % of all marketed drugs during this period . Understanding the molecular mechanism by which a given stimulus activates the corresponding receptor is thus critical for many practical purposes, in particular for the drug discovery process. This requires knowledge of the threedimensional (3D) structure of the receptors and its interaction with ligands.
In the human genome, GPCRs account for about 3 % of all the genes (Fredriksson and Schioth 2005) (900 genes, including 350-400 potentially expressed olfactory receptors, see below). According to the GRAFS classification (Fredriksson et al. 2003) , GPCRs are grouped into five classes: glutamate, rhodopsin, adhesion, frizzled, and secretin.
Hereafter, we will only consider receptors of the rhodopsin class, which contains by far the largest number of receptors. This class is divided into four sub-classes-α, β, γ, and δ, respectively (Fredriksson et al. 2003) . Olfactory receptors (ORs) belong to the δ sub-class and form a monophyletic group. Other groups of the δ sub-class are the MAS-related receptor cluster, the glycoprotein receptor cluster, and the purin receptor cluster.
To date (May 2012), the structure of 14 GPCRs has been elucidated by X-ray crystallography. They all belong to the rhodopsin class, with nine belonging to the α sub-class and five, namely, the chemokine CXCR4, the μ-, δ-, and κ-opioid receptors, and the N/OFQ receptor, belonging to the γ subclass (see Table 1 ). Thompson et al. 2012 ORs are mainly expressed by olfactory sensory neurons in the olfactory epithelium, where their role is to detect and discriminate a very large number of odorant molecules, even at minute concentrations. OR sequences exhibit a poor identity, except for some conserved amino acids, and the ligand binding pocket seems to contain hypervariable residues (Pilpel and Lancet 1999) that are relatively well-conserved between orthologs. This sequence variability explains the ability of ORs to bind a large diversity of odorant molecules that differ in shape (aliphatic, cyclic), length, hydrophobicity, and functional groups. Furthermore, since odorant-OR interactions are mainly hydrophobic, these interactions are relatively weak. Therefore, ligand binding onto ORs is not highly specific, and a single OR can accommodate different odorant molecules. Reciprocally, an odorant molecule can be detected by different ORs, which in turn generates a combinatorial coding starting from the peripheral level (Malnic et al. 1999; Sanz et al. 2005 ). Different odorant molecules activate different-but possibly overlappinggroups of ORs. Thus, odorant molecules with related structures can be perceived differently (Laing et al. 2003) , while molecules which are apparently different but share structural characteristics can trigger similar perceptions (Sanz et al. 2008) . Moreover, some odorants are OR antagonists, i.e., they lower the response of an OR to an odorant stimulation (Oka et al. 2004; Sanz et al. 2005) , which increases odor coding complexity. Finally, we recently demonstrated that ORs can function as homodimers (Wade et al. 2011) . Beginning in 2000, ORs have been repeatedly reported also to be expressed in non-olfactory tissues (De la Cruz et al. 2009; Feldmesser et al. 2006; Zhang et al. 2007 ) where they play additional roles. Some ORs govern sperm chemotaxis (Fukuda and Touhara 2006; Spehr et al. 2004) , inhibit prostate cancer cell proliferation (Neuhaus et al. 2009 ), regulate cell migration and adhesion in muscle (Griffin et al. 2009) , and regulate serotonin secretion of gastro-intestinal cells (Braun et al. 2007; Kidd et al. 2008) . ORs are also reported to be tumor markers (Leja et al. 2009; Weng et al. 2005) . Even though their biological role and their implication in tumor progression still remains elusive (Fujita et al. 2007 ), these ORs could thus constitute both new biomarkers for diagnosis and molecular targets for various cancer therapies (Weigle et al. 2004) .
In this short review, there is not enough room to address a number of topics relevant to the function of GPCRs, which covers the role of allosteric sites (Changeux and Edelstein 2005) , the receptor homo-or heterodimerization that can mediate cross-talks between GPCR pathways (Milligan et al. 2006) , and the study of GPCR activation mechanisms by molecular dynamics simulations (Niv et al. 2006) . Rather, we focus here on GPCR 3D structure modeling and ligand docking.
GPCR 3D structure modeling GPCR modeling has been hampered for a long time by the lack of experimental structures (see Table 2 ). GPCRs, being integral membrane proteins, are intrinsically difficult to crystallize. In addition, some receptors show a basal activity which presumably implies that they can spontaneously switch between an inactive state and an activated one, which makes it even more difficult to obtain crystals. The first GPCR structure with a good resolution (2.8 Å), that of rhodopsin, was elucidated in 2000. Seven more years of extensive research developments were needed to obtain a second GPCR structure (β2 adrenergic receptor; Rasmussen et al. 2007 ). Since then, significant progress in experimental techniques, such as search methods for thermostable mutants that stabilize preferentially one of the above states or the insertion in the third intracellular loop (ICL3) of a globular protein (T4 lysozyme) that facilitates the crystallization process, has allowed crystallographers to elucidate the 3D structure of nine more GPCRs and, for the first time last year, to obtain a series of receptor-agonist complexes showing the activated form of the corresponding receptors. These complexes were stabilized by the introduction of a camelid antibody fragment (nanobody) (Rasmussen et al. 2011a) . A complex of the β2 adrenergic receptor with the Gs α-subunit was also resolved last year (Rasmussen et al. 2011b ). The pace is significantly accelerating-in the first months of 2012 alone seven new structures were released (see Table 1 ).
Characteristics of known GPCR structures
Armed with the knowledge of these new structures, it is now possible to reasonably infer general characteristics of GPCR 3D structures of the rhodopsin class and, conversely, point out the idiosyncracies of specific receptors. GPCRs share a similar organization: an extracellular N-terminus that can exhibit very different lengths, varying from a short unstructured loop in the ORs to large organized globular domains in the glycoproteins receptors, a bundle of seven transmembrane helices connected by three extra-cellular loops (ECLs) and three ICLs, and an eighth helix that lies parallel to the cytoplasmic side of the membrane and is often bound to it via palmitoylation.
Conservation of 7 transmembrane helices The seven-helix bundle is the most structurally conserved region of GPCRs.
The root mean square (RMS) deviations for the helices of 11 of the known structures are shown in Table 3 . Although transmembrane helices (TMHs) share a moderate sequence similarity, even for GPCRs in the same class (see Table 3 ), a number of highly conserved residues and sequence motif signatures have been identified (see Fig. 1 ). Highly conserved residues form the basis of the Ballesteros-Weinstein numbering system (Ballesteros and Weinstein 1995) : Asn in TMH1, Asp in TMH2, Arg in TMH3, Trp in TMH4, and Pro in TMH5, TMH6, and TMH7. Functionally important sequence motifs are also found in the TMHs, such as [DE] RY on TMH3, which is part of the 'ionic lock,' CWxP on TMH6, and NPxxY on TMH7 in which, respectively, the Trp and Tyr are two of the so-called micro-switches (Nygaard et al. 2009 ) which are suspected to be involved in the receptor activation mechanism. It has been observed that the intracellular side of the receptor is better conserved than the extracellular side ). This difference reflects their different roles, with the extracellular side being committed to ligand recognition and the intracellular side committed to downstream signaling.
Structural diversity in loops Loops, as could be expected, display much more variability than TMHs. Again, ECLs show more diversity than ICLs. It is noteworthy that ECLs display highly ordered conformations that are stabilized by disulfide bridges and interactions with the TMHs. This is particularly true of ECL2 which interacts with a number of ligands in the known structures of the complexes. ECL2 links TMH4 and TMH5. However, a highly conserved disulfide bridge exists between a Cys in ECL2 and a Cys in the N-terminal region of THM3. This disulfide bridge defines two pseudo-loops or linkers, namely, ECL2a connecting TMH4 with TMH3 and ECL2b connecting TMH3 to TMH5. ECL2b is important for ligand interaction since it acts as a partial lid on top of the binding pocket. Some of its residues are known to interact with antagonists. ECL1 and ECL3 are relatively short loops with less structural variability. On the intracellular side, ICL1 loops in different receptors display similar backbone conformations. Conversely, ICL2 and ICL3 show high structural flexibility or instability.
Different orientation of side chains in the binding pocket The binding pocket of GPCRs is located approximately in the first one-third of the helical bundle from the extracellular side. GPCRs need to accommodate very different ligands in their binding pocket, a requirement reflected by the diversity of side chain and backbone conformations in both the TMHs and the ECLs of known structures giving rise to pockets with different geometries. Henderson et al. 1990 1993 9 Å projection map of bovine rhodopsin showing the configuration of the helices Schertler et al. 1993 1995 Low-resolution structure of bovine rhodopsin determined by electron cryo-microscopy.
Unger and Schertler 1995
Projection structure of frog rhodopsin in two crystal forms (6 Å resolution)
Schertler and Hargrave 1995 1997 Arrangement of rhodopsin transmembrane alpha-helices.
Estimation of the tilt angles for the seven helices. Construction of an α-carbon template for the trans-membrane helices in the rhodopsin family of G protein-coupled receptors Unger et al. 1997; Baldwin et al. 1997 2000 High-resolution structure of bovine rhodopsin (2. However, models of the same OR sequence constructed using available templates display a good similarity in terms of accessible surface of the residues located in the binding pocket (correlation coefficient of 0.75) (Launay et al. 2012 ). This might be explained by the relative rigidity of the binding pocket. Different crystal structures of the same GPCR with several ligands (agonists or antagonists) show little conformational rearrangements of the binding pocket .
Helical distortion and helix extension A number of helical features differentiate TMHs in the known structures (Worth et al. 2009 ), including helix extensions (e.g., TMH5 and TMH6 in squid rhodopsin), Pro kink or distortion in TMH4, TMH5, TMH6, and TMH7 of most structures, Gly-Gly bulge/distortion (e.g., TMH2 of human or TMH1 of squid rhodopsins), and Gly bend (e.g., TMH3 of human rhodopsin). Some patterns of Pro in the TMH sequence lead to an insertion in the TMHs. For example, the sequence alignment of TMH2 of the chemokine receptor requires the insertion of a gap in its sequence, as predicted by Deville et al. (2008) in their study of helix-X-helix motifs in proteins.
GPCR 3D structure modeling
De novo modeling Most of the models developed in the 1990s were based on de novo methods due to the lack of accurate experimental 3D structures of GPCRs (see Table 2 ). The aim of these methods was to assemble individual helices into a bundle by relying on either lowresolution experimental data or physical-chemical principles. Thus, Baldwin and colleagues proposed an α-carbon template for the transmembrane helices of rhodopsin based on the density in a low-resolution 3D map of frog rhodopsin determined by electron cryomicroscopy. Soon thereafter, Filizola et al. (1998) proposed a program, BUNDLE, for building the transmembrane domains of GPCRs from low-resolution electron density maps of rhodopsin obtained from electron microscopy studies on 2D crystals. In 2000, Floriano et al. (2000) built a model of OR S25 based on the 7.5 Å density map electron density map of rhodopsin using molecular dynamics to refine the model. Fleishman et al. developed score functions and automated methods for orienting TMHs using cryo-EM data (Fleishman et al. 2004 ).
In parallel, novel programs were developed, such as PREDICT (Shacham et al. 2001 (Shacham et al. , 2004 or MEMBSTRUCK (Vaidehi et al. 2002) . These programs were based on physical-chemical considerations, and their aim was to optimize the helical-packing geometry, tilts between the helices, helix orientations, side chain rotamers, helix-membrane crossings, and helical kinks.
In 2006, new methods, based on de novo fragment assembly techniques, were applied to the task of predicting the 3D structure of GPCRs. Zhang and colleagues used TASSER, a threading assembly refinement method, to generate models of all identified human GPCRs (Zhang et al. 2006) . They obtained good results for human rhodopsin, the only known GPCR structure at that time, achieving a global RMS standard deviation (RMSD) of 4.6 Å and a RMSD of 2.1 Å for the helical bundle. Baker's group, who used ROSETTA to predict multipass membrane proteins, obtained a result of 10.2 Å for the structure of rhodopsin and 3.6 Å for the TMHs (Yarov-Yarovoy et al. 2006) .
In 2007, the structure of the β2 adrenergic receptor was solved at a resolution of 2.4 Å (see Table 2 ). Clarification of this structure allowed the direct checking of homology models based on the rhodopsin structure. At that time, there were still discussions about how good a template for modeling other GPCRs rhodopsin was, although models based on rhodopsin had already been indirectly corroborated through a vast array of mutagenesis experiments. Eventually, the new structure (Costanzi 2008) . With the availability of high-resolution GPCR structures, it became possible to combine traditional homology modeling techniques with ligandbased pharmacophore modeling (Mobarec and Filizola 2008; Schlyer and Horuk 2006) .
Homology modeling
The homology modeling procedure consists of four steps (Xiang 2006) : Fig. 1 Eleven G protein-coupled receptor templates and three olfactory receptor multiple sequence alignments. Starting and ending positions of transmembrane helices (TMHs) are indicated. Green boxes highlight conserved positions previously reported in the literature for olfactory receptors. Position 50 of the Ballesteros-Weinstein numbering scheme is shown in orange. N-terminus residues are missing in the X-ray structure for the dopaminergic, histamine H1, and sphyngosine 1-phosphate receptors 1. Identification of at least one homologous protein with a known 3D structure (the structural template); 2. Alignment of the query sequence to the template structure; 3. Construction of the model from the template structure; 4. Assessment and refinement of the model. While the sequence identity between GPCRs is weak, there is usually no difficulty in identifying a GPCR protein from its sequence based on the detection of the TMHs using, for example, Hidden Markov model techniques (e.g., Bagos et al. 2006 ) and the conservation of key residues and functional motifs.
On the other hand, this weak sequence identity has a strong influence on the quality of the sequence-structure alignment. This alignment is the most critical step of the procedure since it is virtually impossible to recover from an alignment error in subsequent steps, resulting in an erroneous model. The difficulty of homology modeling varies strongly according to the similarity existing between the query and the template sequences. It is generally admitted that the alignment of the query and template sequences becomes problematic when the percentage of sequence identity falls to <25 %. Many insertions/deletions in the sequences found in this zone, often called the 'twilight zone,' make it difficult to obtain an accurate alignment. As mentioned above, the sequence identity of most GPCRs with the solved structures lies within this twilight zone. Fortunately, very few insertions/deletions are allowed in the TMHs (TMH2 of the chemokine receptor being one notorious exception) which, combined with the conservation of some key residues and motifs, makes the problem of modeling GPCR structures tractable.
Given the alignment between the query and the template sequences, three main procedures exist to build the model: rigid body assembly (Sutcliffe et al. 1987a, b) , segment matching (Levitt 1992) , and spatial restraint (Sali and Blundell 1993) . These procedures entail the prediction of loops (described in more detail in the next section) and the determination of the side chain conformations. Many side chain conformation prediction programs are based on rotamer libraries, and a variety of approaches have been developed to cope with the combinatorial problem of sampling the side chain conformation space (e.g., Kingsford et al. 2005; Samudrala et al. 2000) .
In terms of model assessment, a number of programs or scoring functions have been developed to check the proper stereochemistry of models (e.g., PROCHECK, Laskowski et al. 1996) or to evaluate the sequence-structure fitness (e.g., VERIFY3D, Eisenberg et al. 1997) , respectively. However, for GPCR modeling, the researcher mostly checks that key residues and functional motifs are properly aligned, and the models are further validated through mutagenesis experiments and/or, as in the case of virtual screening (see below), the effectiveness of new chemical compounds as agonists or antagonists.
Fourteen GPCR structures are now available to be used as templates, and the question now arising is which one is the best template for modeling a given query GPCR. Worth et al. (2009) answered this question by analyzing in detail the sequence motifs and structural features that exist in the known structures and subsequently designing a flow diagram that allows modelers to chose the most relevant template structure, given the specific attributes observed in the query GPCR sequence. Another study has shown that using multiple templates to build a model slightly improves the resulting model (Mobarec et al. 2009 ). Launay et al. (2012) , for the purpose of virtual screening of ligands, advocate the building of multiple models based on all available templates. The goal is to generate the maximum diversity of 3D structures that should provide, ideally, a better coverage of the experimental conformational space of GPCRs. The research group of Abagyan , which was one of the most successful groups in the 2008 GPCRDock contest (Michino and Abola 2009), proposed a similar idea except that multiple conformations of the model were generated using an Elastic Network Normal Mode analysis (Tirion 1996) .
Loop modeling
As mentioned earlier in the section Characteristics of known GPCR structures, loops are the most variable regions of the receptors and the regions where the substitutions, deletions, and insertions in the sequence are concentrated. With the exception of loops that play a direct role in the protein function, such as by being part of the active site in enzymes, and which therefore, in general, are extremely well conserved, loops differ in their conformations. It is seldom possible to use the known conformation of a loop in the template protein to model the conformation of the corresponding loop in the query protein. This is particularly true when insertions/deletions are present, resulting in loops of different lengths. Two strategies are employed to model loop conformations: knowledge-based and de novo/ab initio. In the first approach, the researcher performs a search in protein 3D structure databases for loops of the same length and whose distance between the N-terminal and C-terminal sides corresponds approximately to the distance between the backbone 'stubs' in the model structure to which the loop ought to be connected. This approach works well for relatively short loops, i.e., those less than 6-8 residues long (1.35 Å RMSD for 8-residue loops) (Michalsky et al. 2003) . In the second approach, the researcher samples as exhaustively as possible the conformational space of the loop using detailed physical energy function (e.g., generalized Born solvation model and the AMBER4 force field, Rapp and Friesner 1999) or coarser statistical potential (e.g., DFIRE, Zhang et al. 2004) . The conformational sampling is usually sufficient for loops up to 12 residues long, and if the scoring function is accurate enough, loops of this size can be modeled to 2 Å RMSD. Modeling loops longer than 12 residues remains a difficult task. This is a problem for modeling GPCR ECL2, which is often very long (about 30 residues). Determining the conformation of ECL2 is important since in known structures ECL2 has been shown to interact with ligands (preferentially with antagonists that have a tendency to dock higher than agonists in the binding pocket). It is thus difficult to accurately dock antagonists in the binding pocket if the conformation of ECL2 cannot be precisely determined (Michino and Abola 2009) . Goldfeld et al. (2011) recently succeeded in modeling the ECL2 of β1 and β2 adrenergic receptor (26 residues) to 1.6 and 2.2 Å, respectively, and obtained a fair result of 4.4 Å for ECL2 of the A A2 adenosine receptor, which is longer (36 residues).
Virtual screening
Virtual screening has become an important technique for designing new drugs since it allows pharmaceutical chemists to rapidly scan, in silico, large databases of compounds for the purpose of discovering new 'hits.' The latter are chemical compounds that are capable of binding to the target protein and acting as agonists, inverse agonists, or antagonists. Two approaches are possible for discovering new hits: a ligand-based or pharmacophore-based approach and a structure-based approach, respectively.
Ligand-based approach This type of method can be used in the absence of structural information on the target protein. However, it requires knowledge of a set of active ligands, agonists, or antagonists. The underlying concept is that compounds with similar 'pharmacophoric features' will likely display similar biological responses. A pharmacophore model describes the distribution in space of the functional/chemical groups required to interact with a specific biological target and trigger (or block) its biological response. Pharmacophore models are usually represented as a set of spheres in 3D space with different radii, with each sphere being characteristic of a particular chemical property: hydrogen bond donor or acceptor, hydrophobic, charged, polar, aromatic center, cation, anion, etc. The size of the spheres allows the user to apply more or less stringent conditions on the precise localization of the corresponding chemical/functional group in space. Virtual screening of chemical compounds consists in enumerating multiple conformations for each molecule in the database and checking whether, in the different conformations, their chemical groups can match the pharmacophore model. This approach is very fast, and hundreds of thousands of compounds can be screened within a reasonable computer time. However, it cannot rank the compounds, just cluster them into hits or nonhits, although it is possible to refine the clustering by specifying several broad categories, such as good, medium, and weak (see (Sanz et al. 2008) ). The main limitation of this type of method is that it does not allow the user to understand the molecular mechanisms underlying the biological function of the receptor. In addition, optimization of the initial hits can be challenging due to the lack of information on how ligands bind to their target (Radestock et al. 2008) .
Structure-based approach In this approach, the researcher attempts to identify the mode of interaction of the ligand with the receptor by docking it in the 3D structure. The procedure rests on an exhaustive sampling of the conformational space to locate the relevant binding mode and on the criterion to rank the ligands according to their affinity to the target. With modern computers, sampling the conformational space is not a real problem, particularly when the flexibility of the receptor conformation is not taken into account. By contrast, scoring functions play a critical role in molecular docking. Three kinds of functions are used in docking simulations: physics-based force fields, empirical functions, and knowledge-based functions, respectively. Physics-based force fields, such as AMBER, GROMOS, or CHARMM, are usually demanding in terms of computer power and are relatively sensitive to small inaccuracies in distances; consequently, they require the receptor conformation to be treated as flexible. Entropy and solvation effects must also be properly accounted for. Other functions provide a coarse approximation of the binding free energy. Empirical functions, using a weighted set of features (hydrogen bonds, accessible surface, etc.), try to fit the corresponding terms to experimental data. Knowledge-based functions derive their parameters from observed distances between relevant functional sites in known structures of ligand-receptor complexes. The main advantage of the structure-based approach is that it allows the user to understand the molecular basis of the ligand-receptor interaction and to rationalize how different compounds can activate (or inhibit) the biological response. However, docking is quite sensitive to the accuracy of the receptor structure. A problem can arise when this structure is obtained by homology modeling, and the imprecision of the scoring functions often makes it difficult to correctly rank the ligand poses. Warren and colleagues carried out a very thorough analysis of the strengths and weaknesses of ten docking programs and scoring functions (Warren et al. 2006) , and Sun (Sun 2008 ) has nicely described the pros and cons of the structure-based approach versus the ligand-based approach. Mixed approach It is also possible to incorporate knowledge coming from the ligand-based approach or other experimental information, such as mutational data, to refine the modeling procedure and help in selecting the right ligand pose (Yarnitzky et al. 2010 ). For example, Evers et al. (2003) proposed a ligand-supported homology modeling procedure in which the models are refined iteratively by including information on active ligands as spatial restraints and optimizing the mutual interactions between the ligands and the binding sites. In the GPCRdock contest, in which a number of groups were asked to predict the 3D structure of the complex of the A2A adenosine receptor with an antagonist (ZM241385) before its publication, the most successful predictions were those using this mixed approach Michino and Abola 2009 ).
Application to structure modeling and virtual screening of ORs
Olfactory receptors, despite their low sequence identity with other GPCRs, share a number of sequence features with the latter. Nevertheless, aligning the OR sequences with the sequence of the known structural templates can be challenging for some transmembrane segments. For TMH5 and -6 in ORs, key residues (i.e., those with the number 50 in the Ballesteros-Weinstein numbering scheme) are not conserved, which makes it difficult to lock into place the alignment for these two helices. This is particularly true for TMH6 for which it is very challenging to decide between alternative alignments without experimental clues (Launay et al. 2012) . Obtaining an accurate alignment is critical for subsequent docking studies since, in helices, a shift of one or two positions will cause side chains, which would normally face the lumen of the binding pocket, to point towards another TMH or towards the lipid bilayer, respectively. Other sequence motifs, such as the ionic lock, '[DE]RY,' in TMH3 and 'NPxxY' in TMH7 are conserved, but not 'CWxP' in TMH6. The key residues that are not conserved in TMH5 and TMH6 are both prolines, raising the question of whether the resulting kinked or distorted helices observed in known GPCR structures are good models for TMH5 and TMH6 of ORs.
The ECL2b linker, which acts as a partial lid over the binding pocket and interacts with most antagonists and some agonists in known GPCR structures, appears to be longer in ORs. As discussed above, the accurate modeling of long loops is difficult. For ORs, this point might not be too critical, since odorants are usually low-molecular-weight organic compounds and therefore relatively small compared to the ligands of other GPCRs. A number of OR models in which odorants were docked and which were tested by sitedirected mutations have revealed that odorants dock deep into the pocket (Abaffy et al. 2007; Katada et al. 2005; Launay et al. 2012) and do not interact with ECL2.
Most OR genes have been identified through analyses of sequenced genomes (Fredriksson and Schioth 2005) . Thus, very little information is available on most ORs beyond the amino acid sequence. In particular, the vast majority of ORs are 'orphans,' which means that the odorant molecules they are able to detect are unknown. Virtual screening can only be performed through a structure-based approach. In the near future, an important task will be to try deciphering this largely uncharted 'odor space. ' Reisert and Restrepo (2009) reviewed recent findings of OR responsiveness through a variety of techniques, such as improved OR deorphanization methods, site-directed mutagenesis, structural modeling studies, and studies of OR responses in situ in olfactory sensory neurons. Table 4 presents a summary of the modeling and docking simulations performed with ORs over the years. One of the very first OR models used the seven TMHs of bacteriorhodopsin as the structural template (Oliveira et al. 1993) . However, bacteriorhodopsin is a light-driven proton pump which, despite its name, is not related to rhodopsin-nor to GPCRs in general. It is now known that its seven helices have an organization that differs from that of GPCRs. At the turn of the century, most models were still based on de novo approaches guided by the low-resolution rhodopsin structural data or from first principles (e.g., the works of the Goddard's group). Modeling works were mainly devoted to the task of delineating the binding pocket in ORs. A few more years of such research resulted in the first homology models based on the 2.8 Å resolution structure of bovine rhodopsin (as mentioned above, during this period, issues about the soundness of rhodopsin as a generalizable model for GPCRs were still being debated). At the same time, some groups (Katada et al. 2005) started to probe the results of the modeling and docking simulations by performing site-directed mutagenesis experiments and functional assays. After the elucidation of a second GPCR structure in 2007, that of the human β2 adrenergic receptor, questions related to the applicability of rhodopsin as a model for other GPCR structures were eventually settled, and most models were then based on the homology modeling approach using the available high-resolution GPCR structures as templates. After 2005, the results of the OR modeling and ligand docking in silico simulations were systematically validated by site-directed mutagenesis experiments and functional assays in an effort to better understand the characteristics of ligand recognition by ORs [screening of large odorant libraries and determination of functional fingerprints (Baud et al. 2010) , characterization of 'odotypes' (Schmiedeberg et al. 2007; Stary et al. 2007) , correlation between the ligand concentration required for 50 % activation of the receptor (EC50), and the computed binding energy (Kurland et al. 2010) , among others]. Due to the difficulty of aligning some of the OR TMHs, most proposed models 2.8 Å bovine rhodopsin 3D structure Schmiedeberg et al. 2007 This work is related to that in (Stary et al. 2007 ). Using site-directed mutagenesis and functional expression the authors show that the orientation of odorants within a homo logy modelingderived binding pocket of olfactory receptor orthologs is defined by evolutionary conserved amino acid positions. mOR42-3, mOR42-1 2.8 Å bovine rhodopsin 3D structure Abaffy et al. 2007 Investigation of the specificity of mOR42-3 for dicarboxylic acids. Use of site-directed mutagenesis to locate functionally important residues. Mapping of relevant residues in TMH3, 5, and 6. mOR-EG 2.4 Å β2-adrenergic receptor 3D structure 2010 Baud et al. 2010 Screening of a large odorant library allowed the authors to discover a wide range of chemical compounds activating mOR-EG. Residues responsible for the ligand recognition were probed by mutagenesis experiments. Eleven residues were identified as part of the receptor binding pocket thus revealing functional 'fingerprints' of ligand-receptor interactions. rOR-I7 2.2 Å resolution bovine rhodopsin 2010 Kurland et al. 2010 The authors studied the discrimination of n-alkyl saturated aldehydes by rOR-I7. They determined the concentration of odorant required for 50 % activation of the receptor (EC 50 ) measured by calcium imaging. These concentrations showed a good correlation with the corresponding binding free energies computed from the in silico model. hOR-2AG1 2.2 Å resolution bovine rhodopsin 2012 Gelis et al. 2012 The authors studied residues in the binding pocket (niche) involved in the recognition of amylbutyrate by hOR-2AG1 employing a combination of molecular dynamics, site-directed mutageneis and functional ana-lysis of receptor mutants by calcium imaging. hOR-1G1 2.2 Å bovine rhodopsin, 2.4 Å β2 adrenergic, 2.7 Å β1 adrenergic, 2.6 Å A2A adenosine, 2.5 Å chemokine CXCR4 and 2.9 Å dopamine receptor 3D structures Launay et al. 2012 Models of hOR-1G1 were obtained in a completely automatic way with all the (then) available templates. A fold recognition technique was employed to align TMHs, in particular TMH5 and TMH6 that have no conserved key residues. Some important residues in the binding pocket were probed by site-directed mutagenesis and functional analysis of receptor mutants by calcium imaging. It was proposed that the difference in agonist potencies lies in the ability of the ligand to interact with the bottom of the binding pocket. needed to be 'handcrafted' by experts, often with the help of experimental data. Launay et al. (2012) recently proposed an automatic pipeline to model ORs that is based on fold recognition techniques to obtain accurate alignments and which employs all available GPCR templates. This pipeline also allows users to dock various ligands in the generated models (http://genome.jouy.inra.fr/GPCRautomodel).
Conclusion
Analyses of GPCRs by in silico methods (structure modeling and virtual screening) have long been plagued by the lack of template 3D structures. The last 5 years have seen remarkable progress in the ability of X-ray crystallographers to solve new GPCR structures, resulting in a more than tenfold increase in the number of existing structures (from 1 to 14). It is notable that seven new structures were released in the first months of 2012 (including three while the manuscript was under review), indicating that the pace of solving GPCR structure is accelerating. It is now important to fully benefit from this wealth of experimental data, including data on the structure of activated receptors, to study the characteristics of new GPCRs. Structure modeling and virtual screening have proven to be very valuable methods, in combination with other experimental techniques, such as nuclear magnetic resonance, site-directed mutagenesis, functional assays using calcium imaging, electrophysiology, or surface plasmon resonance, by which to gain insight into the properties of GPCRs and to shorten the time needed for designing new drugs targeted at this family of receptors. However, there is no structure of a GPCR close to the OR cluster as yet. ORs show specificities compared to those GPCRs whose structures have been solved; in particular, they do not have a single cognate ligand. Some of their TMHs are difficult to align due to the absence of wellconserved residues, perhaps indicating a different mechanism of activation. To further decipher the biochemical mechanisms used by evolution to tune the mammalian olfactory repertoire, it is essential to maintain a tight interplay between in silico simulations and experimental validations.
